Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 1;64(11):1582-1588.
doi: 10.1093/cid/cix184.

The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-Lactams

Affiliations

The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-Lactams

Nicolas Dufour et al. Clin Infect Dis. .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Clin Infect Dis. 2017 Oct 15;65(8):1431-1433. doi: 10.1093/cid/cix563. Clin Infect Dis. 2017. PMID: 29017252 Free PMC article. No abstract available.

Abstract

Background.: Other than numerous experimental data assessing phage therapy efficacy, questions regarding safety of this approach are not sufficiently addressed. In particular, as phages can kill bacterial cells within <10 minutes, the associated endotoxin release (ER) in severe infections caused by gram-negative bacteria could be a matter of concern.

Methods.: Two therapeutic virulent phages and 4 reference antibiotics were studied in vitro for their ability to kill 2 pathogenic strains of Escherichia coli and generate an ER. The early interaction (first 3 hours) between these actors was assessed over time by studying the instantaneous cell viability, the colony-forming unit count, the concentration of free endotoxin released, and the cell morphology under light microscope.

Results.: While β-lactams have a relatively slow effect, both tested phages, as well as amikacin, were able to rapidly abolish the bacterial growth. Even when considering the fastest phage (cell lysis in 9 minutes), the concentrations of phage-induced ER never reached the highest values, which were recorded with antibiotic treatments. Cumulative concentrations of endotoxin over time in phage-treated conditions were lower than those observed with β-lactams and close to those observed with amikacin. Whereas β-lactams were responsible for strong cell morphology changes (spheroplast with imipenem, filamentous cells with cefoxitin and ceftriaxone), amikacin and phages did not modify cell shape but produced intracellular inclusion bodies.

Conclusions.: This work provides important and comforting data regarding the safety of phage therapy. Therapeutically relevant phages, with their low endotoxin release profile and fast bactericidal effect, are not inferior to β-lactams.

Keywords: cell lysis; endotoxin; phage therapy; safety; β-lactams..

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Colony-forming unit (CFU) counts of strains LM33 and 536 according to time. Strain LM33 (A) and strain 536 (B) were cultured in absence (control) or presence of antibacterial agents: phages (LM33_P1 or 536_P1, multiplicity of infection of 5) or antibiotics (8-fold the minimum inhibitory concentration). Data are means with standard deviation, and the dotted line represents the detection threshold.
Figure 2.
Figure 2.
Relative amount of metabolically active cells according to time in presence of different antibacterial agents. Strain LM33 (A) and strain 536 (B) were cultured in absence (control) or presence of antibacterial agents: phages (LM33_P1 or 536_P1, multiplicity of infection of 5) or antibiotics (8-fold the minimum inhibitory concentration). The viable cells were quantified using an ATP-driven luciferase assay (see Methods). Data are means with standard deviation and the y-axis is in log2 scale. Abbreviation: RLU, relative luminescence unit.
Figure 3.
Figure 3.
Morphology of Escherichia coli cells after a 3-hour exposition to different antibacterial agents. The liquid cultures of strains LM33 and 536 in absence (control) or presence of antibacterial agents (antibiotics with a concentration of 8-fold the minimum inhibitory concentration, phages LM33_P1 or 536_P1 with a multiplicity of infection of 5) were centrifuged to concentrate the residual biomass. Wet mount preparations were then observed under phase contrast (×100 lens).
Figure 4.
Figure 4.
Concentration of free endotoxin released in the culture medium over time by cells exposed to different antibacterial agent. Strain LM33 (A) and strain 536 (B) were cultured in presence of phages (LM33_P1 or 536_P1, multiplicity of infection of 5) or antibiotics (8-fold the minimum inhibitory concentration). The symbols are the means of 2 independent experiments with standard deviation. The curves are nonlinear regressions from these points (see Methods). Abbreviation: EU, endotoxin unit.
Figure 5.
Figure 5.
Areas under the concentration of free endotoxin vs time curve (0 to 180 minutes). Strain LM33 (left side) and strain 536 (right side) were cultured in presence of phages (respectively, LM33_P1 and 536_P1, multiplicity of infection of 5) or antibiotics (8-fold the minimum inhibitory concentration). Data are means with standard deviation. Abbreviations: AUC, area under the curve; EU, endotoxin unit.

Comment in

References

    1. World Health Organization. Implementation of the global action plan on antimicrobial resistance. WHO GAP AMR Newsletter. Geneva, Switzerland: WHO, 2016.
    1. Kingwell K. Bacteriophage therapies re-enter clinical trials. Nat Rev Drug Discov 2015; 14:515–6. - PubMed
    1. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009; 34:349–57. - PubMed
    1. Sarker SA, Sultana S, Reuteler G, et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 2016; 4:124–37. - PMC - PubMed
    1. Viertel TM, Ritter K, Horz HP. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J Antimicrob Chemother 2014; 69:2326–36. - PubMed

MeSH terms